Giuseppe
Emeritus
In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. (Antimicrob Agents Chemoter., abstract, edited)
[Source: US National Library of Medicine, (LINK). Edited.]
Antimicrob Agents Chemother. 2010 Mar 29. [Epub ahead of print]
In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. - Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Toyama Chemical Co., Ltd., Tokyo, Japan.
Favipiravir (T-705) has previously been shown to have a potent antiviral effect against influenza virus and some other RNA viruses in both cell culture and in animal models. Currently, favipiravir is undergoing clinical evaluation for the treatment of influenza A and B virus infections. In this study, favipiravir was evaluated in vitro for its ability to inhibit the replication of a representative panel of seasonal influenza viruses, the 2009 A(H1N1) strains and animal viruses with pandemic potential (swine triple-reassortants, H2N2, H4N2, avian H7N2, and avian H5N1), including viruses which are resistant to the currently licensed anti-influenza drugs. All viruses were tested in a plaque reduction assay in MDCK cells, and a subset was also tested in both yield reduction and focus inhibition assays. For the majority of viruses tested, favipiravir significantly inhibited plaque formation at 3.2 muM (0.5mug/ml) (EC50s 0.19 - 22.48 muM, 0.03 - 3.53 mug/ml), and for all viruses, with the exception of a single dual resistant 2009 A(H1N1) virus, complete inhibition of plaque formation was seen at 3.2 muM (0.5mug/ml). Due to the 2009 pandemic and increased drug resistance in circulating seasonal influenza viruses, there is an urgent need for new drugs which target influenza. This study demonstrates that favipiravir inhibits in vitro replication of a wide range of influenza viruses, including those resistant to currently available drugs.
PMID: 20350949 [PubMed - as supplied by publisher]
-
------
[Source: US National Library of Medicine, (LINK). Edited.]
Antimicrob Agents Chemother. 2010 Mar 29. [Epub ahead of print]
In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. - Virus Surveillance and Diagnosis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Toyama Chemical Co., Ltd., Tokyo, Japan.
Favipiravir (T-705) has previously been shown to have a potent antiviral effect against influenza virus and some other RNA viruses in both cell culture and in animal models. Currently, favipiravir is undergoing clinical evaluation for the treatment of influenza A and B virus infections. In this study, favipiravir was evaluated in vitro for its ability to inhibit the replication of a representative panel of seasonal influenza viruses, the 2009 A(H1N1) strains and animal viruses with pandemic potential (swine triple-reassortants, H2N2, H4N2, avian H7N2, and avian H5N1), including viruses which are resistant to the currently licensed anti-influenza drugs. All viruses were tested in a plaque reduction assay in MDCK cells, and a subset was also tested in both yield reduction and focus inhibition assays. For the majority of viruses tested, favipiravir significantly inhibited plaque formation at 3.2 muM (0.5mug/ml) (EC50s 0.19 - 22.48 muM, 0.03 - 3.53 mug/ml), and for all viruses, with the exception of a single dual resistant 2009 A(H1N1) virus, complete inhibition of plaque formation was seen at 3.2 muM (0.5mug/ml). Due to the 2009 pandemic and increased drug resistance in circulating seasonal influenza viruses, there is an urgent need for new drugs which target influenza. This study demonstrates that favipiravir inhibits in vitro replication of a wide range of influenza viruses, including those resistant to currently available drugs.
PMID: 20350949 [PubMed - as supplied by publisher]
-
------